Dermal and Subcutaneous Augmentation and Skin Assessment After Fat-, Stem Cell and Scaffold Injections

NCT ID: NCT05079243

Last Updated: 2022-11-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-04

Study Completion Date

2023-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigate the effect of dermal/subcutaneous injection of ASC enriched fat transplant in a protective natural scaffold, designed to sustain the ASC viability after dermal/subcutaneous injection.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study investigates the effect of different concentrations of autologous ex-vivo expanded adipose-derived stromal cells (ASCs), fat and a natural scaffold for skin rejuvenation and augmentation. The aim is to better the volume of fat grafts for cosmetic and reconstructive purposes. Fat is a near ideal filler, as it is biocompatible. However the retention rate of fat grafts often result in poor outcomes and it is unpredictable. The investigators have set up an experimental study in which participants with excess abdominal skin is recruited. They will have injections with 11 different solutions of fat, ACSs, scaffold and dermal CO2 laser in the abdominal skin. After 3 months biopsies will be taken and after 6 months all of the treated area will be removed by an cosmetic abdominoplasty.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Augmentation Reconstruction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Triple blinded, randomized, paired study on healthy participants
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Scaffold and adipose-derived stromal cell enriched fat grafts

Randomized and paired injections. Each participant will receive all 11 solutions.

Group Type EXPERIMENTAL

Scaffold and adipose-derived stromal cell enriched fat grafts

Intervention Type BIOLOGICAL

eight different solutions of fat, ASCs, scaffold and CO2 laser in dermis three different solutions of fat, ASCs and scaffold in the subcutaneous layer

Controls samples

Control samples of untreated skin

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Scaffold and adipose-derived stromal cell enriched fat grafts

eight different solutions of fat, ASCs, scaffold and CO2 laser in dermis three different solutions of fat, ASCs and scaffold in the subcutaneous layer

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI between 18-30 kg/m2
* 400 mL of fat (lipoaspirate) available for liposuction in the thighs or back
* Desire for abdominoplasty
* Speaks and reads Danish
* Signed informed consent

Exclusion Criteria

* Smoking
* Previous major abdominal surgery
* Previous cancer or predisposition to cancer
* Pregnancy or planned pregnancy
* Known chronic disease associated with metabolic malfunction or poor healing
* Pacemaker
* Allergy to necessary anaesthesia
* Intention of significant weight loss or weight gain within the trial period
Minimum Eligible Age

25 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rigshospitalet, Denmark

OTHER

Sponsor Role collaborator

Aleris-Hamlet Hospitaler København

OTHER

Sponsor Role collaborator

Stemform

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Frederik P Mamsen

Role: PRINCIPAL_INVESTIGATOR

StemMedical A/S

stig-Frederik T Koelle, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

StemMedical A/S

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aleris Hamlet

Copenhagen, Søborg, Denmark

Site Status

StemMedical

Copenhagen, Søborg, Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H-21004160

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Acellular Adipose Tissue (AAT) for Soft Tissue Reconstruction
NCT03544632 ENROLLING_BY_INVITATION PHASE2
Microsurfaced Grafts in Deep Burn Wounds
NCT04589442 RECRUITING PHASE4